The average heart beats about 1.5 million times over two weeks, and physicians might have to identify a six-second time period, which can determine a clinical outcome. Finding what’s clinically meaningful can be a needle in the haystack type of problem, and AI ensures higher accuracy at scale.
VivaLNK is currently developing a cardiac device, which is the centerpiece of a new platform with the capability to diagnose a-fibrillation more quickly and efficiently than traditional clinical standards.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Geneva Health Solutions' cloud-based technology platform and remote monitoring service will be used to help Ochsner's patients with cardiac device implants in Louisiana, Arkansas, Mississippi, Alabama and Georgia.
Earlier this year the company signed an exclusive distribution deal with Biotronik to expand access to the device.